Peripheral vascular endothelial growth factor as a novel depression biomarker: a meta-analysis

Carvalho, André F., Köhler, Cristiano A., McIntyre, Roger S., Knöchel, Christian, Brunoni, André R., Thase, Michael E., Quevedo, João, Fernandes, Brisa S. and Berk, Michael 2015, Peripheral vascular endothelial growth factor as a novel depression biomarker: a meta-analysis, Psychoneuroendocrinology, vol. 62, pp. 18-26, doi: 10.1016/j.psyneuen.2015.07.002.

Attached Files
Name Description MIMEType Size Downloads

Title Peripheral vascular endothelial growth factor as a novel depression biomarker: a meta-analysis
Author(s) Carvalho, André F.
Köhler, Cristiano A.
McIntyre, Roger S.
Knöchel, Christian
Brunoni, André R.
Thase, Michael E.
Quevedo, João
Fernandes, Brisa S.
Berk, MichaelORCID iD for Berk, Michael
Journal name Psychoneuroendocrinology
Volume number 62
Start page 18
End page 26
Total pages 9
Publisher Elsevier
Place of publication Amsterdam, The Netherlands
Publication date 2015
ISSN 1873-3360
Keyword(s) Biomarker
Major depressive disorder
Neuronal plasticity
Vascular endothelial growth factor
Summary BACKGROUND: The neurotrophic hypothesis of major depressive disorder (MDD) postulates that the pathology of this illness incorporates a down-regulation of neurotrophin signaling. Brain-derived neurotrophic factor (BDNF) is the most studied neurotrophic mediator regarding the neurobiology of MDD. Nevertheless, emerging evidence has implicated the multi-competent angiogenic and neurogenic molecule - vascular endothelial growth factor (VEGF) - in hippocampal neurogenesis and depression pathophysiology. OBJECTIVE: To compare peripheral levels of VEGF between individuals with MDD and healthy controls. METHODS: We performed a systematic review and meta-analysis of original studies measuring peripheral levels of VEGF in participants with MDD compared to healthy controls. We searched the Pubmed/MEDLINE, EMBASE and PsycInfo databases for studies published in any language through December 16th, 2014. RESULTS: Fourteen studies met eligibility criteria (N=1633). VEGF levels were significantly elevated in individuals with MDD when compared to healthy controls (Hedges's g=0.343; 95% CI: 0.146-0.540; P<0.01). Funnel plot inspection and the Egger's test did not provide evidence of publication bias. A significant degree of heterogeneity was observed (Q=38.355, df=13, P<0.001; I(2)=66.1%), which was explored through meta-regression and subgroup analyses. Overall methodological quality, sample for assay (plasma versus serum), as well as the matching of MDD and control samples for age and gender emerged as significant sources of heterogeneity. CONCLUSIONS: Taken together, extant data indicate that VEGF shows promise as a biomarker for MDD, and supports that this mediator may be involved in neuroplasticity mechanisms underlying the pathophysiology of MDD.
Language eng
DOI 10.1016/j.psyneuen.2015.07.002
Field of Research 111714 Mental Health
Socio Economic Objective 920410 Mental Health
HERDC Research category C1 Refereed article in a scholarly journal
Copyright notice ©2015, Elsevier
Persistent URL

Document type: Journal Article
Collections: Faculty of Health
School of Medicine
Connect to link resolver
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 54 times in TR Web of Science
Scopus Citation Count Cited 54 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 691 Abstract Views, 3 File Downloads  -  Detailed Statistics
Created: Thu, 22 Oct 2015, 14:51:10 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact